Login to Your Account



ADA Roundup


Monday, June 11, 2012

• Zafgen Inc., of Cambridge, Mass., presented new data from two Phase I studies that showed beloranib, a selective methionine aminopeptidase 2 inhibitor, led to significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription